Insider Shareholders with Direct Ownership of Iovance Biotherapeutics, Inc. (IOVA)
This section provides a comprehensive overview of the insiders with direct ownership of Iovance Biotherapeutics, Inc. (IOVA). You can find detailed information about the size and nature of each insider's ownership stake, as well as the latest updates on their holdings.
IOVANCE BIOTHERAPEUTICS, INC. Insider List
| Insider | Adquired | Disposed | Held | # of Trades | Last Transaction |
|---|---|---|---|---|---|
|
Frederick G Vogt
Interim CEO & General Counsel |
595,731 | 246,085 | 349,646 $1.24 Million | 30 |
Mar 03, 2025
Reduced 21.44%
|
|
Merrill A Mcpeak
Director |
310,000 | 0 | 320,150 $1.14 Million | 4 |
Feb 20, 2024
Added 43.85%
|
|
Raj K. Puri
Chief Regulatory Officer |
76,667 | 26,252 | 201,252 $716,457 | 6 |
Mar 14, 2025
Reduced 1.23%
|
|
Michael Weiser
Director |
10,000 | 0 | 112,632 $400,969 | 1 |
May 31, 2022
Added 6.49%
|
|
Finckenstein Friedrich Graf
Chief Medical Officer |
186,407 | 93,494 | 92,913 $330,770 | 32 |
Mar 03, 2025
Reduced 26.48%
|
|
Igor Bilinsky
Chief Operating Officer |
181,603 | 94,025 | 87,578 $311,777 | 32 |
Mar 03, 2025
Reduced 27.55%
|
|
Jean Marc Bellemin
Chief Financial Officer |
119,728 | 63,524 | 56,204 $200,086 | 8 |
Mar 03, 2025
Reduced 36.09%
|
|
Iain D. Dukes
Director |
42,000 | 0 | 54,000 $192,240 | 2 |
Feb 20, 2024
Added 37.21%
|
|
Ryan D Maynard
Director |
57,500 | 50,000 | 7,500 $26,700 | 3 |
Nov 12, 2024
Reduced 86.96%
|